- Home
- CTSO
as 07-26-2024 4:00pm EST
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Upcoming Earnings Alert:
Get ready for potential market movements as Cytosorbents Corporation CTSO prepares to release earnings report on 30 Jul 2024.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 55.7M | IPO Year: | N/A |
| Target Price: | $2.67 | AVG Volume (30 days): | 139.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $3.80 | Next Earning Date: | 07-30-2024 |
| Revenue: | $36,686,175 | Revenue Growth: | 3.50% |
| Revenue Growth (this year): | 10.85% | Revenue Growth (next year): | 18.58% |
Stock Insider Trading Activity of Cytosorbents Corporation (CTSO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sobel Alan D. | CTSO | Director | Dec 13 '23 | Buy | $1.33 | 22,557 | $30,000.81 | 101,857 | SEC Form 4 |
| Deliargyris Efthymios | CTSO | Chief Medical Officer | Dec 13 '23 | Buy | $1.33 | 22,557 | $30,000.81 | 348,433 | SEC Form 4 |
| Kim Jiny | CTSO | Director | Dec 13 '23 | Buy | $1.33 | 7,519 | $10,000.27 | 77,819 | SEC Form 4 |
| BLOCH KATHLEEN P. | CTSO | Chief Financial Officer | Dec 13 '23 | Buy | $1.33 | 37,594 | $50,000.02 | 467,941 | SEC Form 4 |
| Capponi Vincent | CTSO | President & COO | Dec 13 '23 | Buy | $1.33 | 18,797 | $25,000.01 | 584,134 | SEC Form 4 |
| BATOR MICHAEL G. | CTSO | Director | Dec 13 '23 | Buy | $1.33 | 37,594 | $50,000.02 | 125,394 | SEC Form 4 |
| Chan Phillip P. | CTSO | Chief Executive Officer | Dec 13 '23 | Buy | $1.33 | 75,188 | $100,000.04 | 1,068,704 | SEC Form 4 |
Latest Cytosorbents Corporation News
CTSO Breaking Stock News: Dive into CTSO Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
GlobeNewswire
25 days ago
CytoSorbents Secures $20 Million Credit Facility
MT Newswires
a month ago
CytoSorbents' Blood Purification Device Gets Approval in Taiwan
GlobeNewswire
a month ago
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
GlobeNewswire
a month ago
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
Compare CTSO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTSO Cytosorbents Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.